These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 23485655)

  • 21. Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study).
    Nguyen QD; Schachar RA; Nduaka CI; Sperling M; Klamerus KJ; Chi-Burris K; Yan E; Paggiarino DA; Rosenblatt I; Aitchison R; Erlich SS;
    Ophthalmology; 2012 Sep; 119(9):1867-73. PubMed ID: 22683252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ranibizumab for the treatment of exudative age-related macular degeneration associated with retinal pigment epithelial tear.
    Rouvas AA; Ladas ID; Georgalas I; Vergados I; Papakonstantinou D; Kotsolis AI
    Retina; 2011 Jun; 31(6):1083-8. PubMed ID: 21427630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improvement of photoreceptor integrity and associated visual outcome in neovascular age-related macular degeneration.
    Kim YM; Kim JH; Koh HJ
    Am J Ophthalmol; 2012 Jul; 154(1):164-173.e1. PubMed ID: 22541932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epimacular brachytherapy for neovascular age-related macular degeneration (CABERNET): fluorescein angiography and optical coherence tomography.
    Jackson TL; Dugel PU; Bebchuk JD; Smith KR; Petrarca R; Slakter JS; Jaffe GJ; Nau JA;
    Ophthalmology; 2013 Aug; 120(8):1597-603. PubMed ID: 23490325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined fluorescein angiography and spectral-domain optical coherence tomography imaging of classic choroidal neovascularization secondary to age-related macular degeneration before and after intravitreal ranibizumab injections.
    Coscas F; Querques G; Forte R; Terrada C; Coscas G; Souied EH
    Retina; 2012 Jun; 32(6):1069-76. PubMed ID: 22466476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
    Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
    Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
    Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G;
    Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
    Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fixed-interval versus OCT-guided variable dosing of intravitreal bevacizumab in the management of neovascular age-related macular degeneration: a 12-month randomized prospective study.
    El-Mollayess GM; Mahfoud Z; Schakal AR; Salti HI; Jaafar D; Bashshur ZF
    Am J Ophthalmol; 2012 Mar; 153(3):481-489.e1. PubMed ID: 22014603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes.
    Baek JS; Cho HJ; Cho SW; Kim CG; Kim JW
    Retina; 2013 Mar; 33(3):467-73. PubMed ID: 23400082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact.
    Shienbaum G; Gupta OP; Fecarotta C; Patel AH; Kaiser RS; Regillo CD
    Am J Ophthalmol; 2012 Mar; 153(3):468-473.e1. PubMed ID: 21996309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravitreal bevacizumab versus combined intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration: six-month results of a randomized clinical trial.
    Ahmadieh H; Taei R; Riazi-Esfahani M; Piri N; Homayouni M; Daftarian N; Yaseri M
    Retina; 2011 Oct; 31(9):1819-26. PubMed ID: 21555967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravitreal bevacizumab for exudative age-related macular degeneration in clinical practice.
    Jonas JB; Tao Y; Schlichtenbrede FC
    J Ocul Pharmacol Ther; 2011 Oct; 27(5):467-70. PubMed ID: 21682590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preferential hyperacuity perimeter as a functional tool for monitoring exudative age-related macular degeneration in patients treated by intravitreal ranibizumab.
    Querques G; Querques L; Rafaeli O; Canoui-Poitrine F; Bandello F; Souied EH
    Invest Ophthalmol Vis Sci; 2011 Sep; 52(9):7012-8. PubMed ID: 21885622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.
    Kumar N; Marsiglia M; Mrejen S; Fung AT; Slakter J; Sorenson J; Freund KB
    Retina; 2013 Sep; 33(8):1605-12. PubMed ID: 23549101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of spectral-domain and time-domain optical coherence tomography in the detection of neovascular age-related macular degeneration activity.
    Major JC; Wykoff CC; Mariani AF; Chen E; Croft DE; Brown DM
    Retina; 2014 Jan; 34(1):48-54. PubMed ID: 23764967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Age-related macular degeneration and risk factors for the development of choroidal neovascularisation in the fellow eye: a 3-year follow-up study.
    Silva R; Cachulo ML; Fonseca P; Bernardes R; Nunes S; Vilhena N; Faria de Abreu JR
    Ophthalmologica; 2011; 226(3):110-8. PubMed ID: 21822000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantification of the therapeutic response of intraretinal, subretinal, and subpigment epithelial compartments in exudative AMD during anti-VEGF therapy.
    Golbaz I; Ahlers C; Stock G; Schütze C; Schriefl S; Schlanitz F; Simader C; Prünte C; Schmidt-Erfurth UM
    Invest Ophthalmol Vis Sci; 2011 Mar; 52(3):1599-605. PubMed ID: 21051733
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of features on SD-OCT between acute central serous chorioretinopathy and exudative age-related macular degeneration.
    Ahn SJ; Kim TW; Huh JW; Yu HG; Chung H
    Ophthalmic Surg Lasers Imaging; 2012; 43(5):374-82. PubMed ID: 22767337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bilateral intravitreal bevacizumab injection for exudative age-related macular degeneration: effect of baseline visual acuity.
    Jonas JB; Tao Y; Rensch F
    J Ocul Pharmacol Ther; 2011 Aug; 27(4):401-5. PubMed ID: 21810019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.